Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,922 recruiting studies in this area right now.
By phase
- Not applicable2,026
- Phase 21,073
- Phase 1790
- Phase 1/Phase 2479
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease133
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California395
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,922 total
- NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Birmingham, AlabamaAges 18 years+ - NCT06463691RecruitingPhase 2
Sonrotoclax, Zanubrutinib, and CD20 Antibody for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs—sonrotoclax, zanubrutinib, and a CD20 antibody—as a first treatment for mantle cell lymphoma. It aims to see if this new combination is safe and effective for patients who have not yet received any treatment.
TianjinAges 18 years+ - NCT07117422Recruiting
Venetoclax and decitabine for untreated AML in older or frail adults
This study tests a combination of two oral and IV medicines (venetoclax and decitabine) for older adults or people who cannot receive strong chemotherapy for newly diagnosed acute myeloid leukemia (AML). The goal is to see if this gentler treatment can help control the disease with fewer side effects.
HebeiAges 65 years+ - NCT07121140Recruiting
Home blood transfusions for cancer patients
This trial tests whether it is safe to give blood transfusions at home instead of in the hospital. It is for people who need regular blood transfusions for their cancer care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07116772Recruiting
Fertility experiences in sickle cell anemia
This study looks at fertility in people with sickle cell anemia. It aims to understand how the disease and its treatments affect fertility over time.
Santo DomingoAges 8 years+ - NCT07117903Recruiting
Ketogenic diet follow-up study in Shanghai
This study follows up with people who completed the first Zhongshan Ketogenic Diet Study in 2025. It looks at the long-term effects of the diet. You may be eligible if you live in Shanghai and took part in the earlier study.
Shanghai, Shanghai MunicipalityAges 18–60 - NCT07115667RecruitingPhase 2
Radiation and antibody therapy for bone plasmacytoma
This trial tests a new combination of radiation therapy and a bispecific antibody (a drug that helps your immune system attack cancer cells) for people with a single bone plasmacytoma that has only a small number of abnormal cells in the bone marrow. It aims to see if this approach can control the disease better than radiation alone.
TianjinAges 18–78 - NCT07122674Recruiting
New PET scan for blood cancers
This study tests a new PET scan method (using a special tracer called 18F-Pentixafor) to see if it can better find and track blood cancers. It may help your doctors get more detailed images with less radiation.
Hangzhou, ZhejiangAges 18–80 - NCT07115654RecruitingPhase 2
A bispecific antibody trial for POEMS syndrome
This trial tests a new drug, BCMA/CD3 bispecific antibody, for people with POEMS syndrome. The drug helps the immune system attack abnormal plasma cells that cause the disease. It may offer a new treatment option for those who haven't had prior anti-plasma cell therapy.
TianjinAges 18–78 - NCT07117136Recruiting
Blinatumomab after standard treatment for B-ALL
This trial is studying how well the drug blinatumomab works for adults with B-cell acute lymphoblastic leukemia (B-ALL) when it is given after the first phase of treatment. It looks at patient data to understand real-world outcomes.
Jacksonville, FloridaAges 18 years+ - NCT07119970Recruiting
NETosis markers for predicting blood clots in MPN
This study looks at certain markers in the blood to see if they can predict blood clots in people with myeloproliferative neoplasms (MPN) like polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. It is only for people who have a specific JAK2 mutation and are at high risk for clots, and who are already enrolled in another trial and a biobank.
AngersAges 18 years+ - NCT07120633Recruiting
CAR-T cell therapy plus BTK inhibitor for high-risk CLL/SLL
This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.
Xuzhou, JiangsuAges 18 years+ - NCT06752746RecruitingPhase 1
Testing 9MW3011 for polycythemia vera in resistant patients
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
Zhengzhou, HenanAges 18 years+ - NCT05882175Recruiting
Checking how well an index predicts blood cancer care
This trial looks at how well a measurement called the OHI Index works for people with blood cancers. It may help doctors better assess risk or needs, but it mainly focuses on validating the tool rather than testing a new drug.
Kfar SabaAges 18 years+ - NCT07113743Enrolling by invitationPhase 1/Phase 2
Gene therapy for x-linked chronic granulomatous disease
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
Bethesda, MarylandAges 3–60 - NCT07107529RecruitingPhase 2
Study of daratumumab with teclistamab or talquetamab for frail patients with newly diagnosed multiple myeloma
This trial tests a combination of drugs—daratumumab plus either teclistamab or talquetamab—for people who have just been diagnosed with multiple myeloma and are considered frail. The goal is to see if this treatment is safe and effective for those who may not be strong enough for standard therapies.
Ascoli PicenoAges 18 years+ - NCT07112378RecruitingPhase 3
Study of dupilumab for young children with eosinophilic esophagitis
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
Phoenix, ArizonaAges 6 months–6 years - NCT07113925RecruitingPhase 1
Testing TQB2101 for advanced blood cancers
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
Zhengzhou, HenanAges 18–75 - NCT07115004RecruitingPhase 3
Testing an injectable drug for von Willebrand disease
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
Little Rock, ArkansasAges 12–75 - NCT07114367RecruitingPhase 1
NB02 for relapsed non-Hodgkin's lymphoma
This trial tests a new oral drug (NB02) for people with certain types of non-Hodgkin's lymphoma that have come back or not responded to at least two prior treatments. It aims to see if the drug can shrink tumors and control the disease.
HwasunAges 19–80 - NCT07107126RecruitingPhase 1
Testing a new drug for relapsed AML or high-risk MDS
This trial tests a new drug called RPT1G for adults with acute myeloid leukemia or high-risk myelodysplastic syndromes that have not responded to standard treatments. The goal is to see if the drug is safe and if it shows signs of helping control the disease.
New York, New YorkAges 18 years+ - NCT06747364Recruiting
Blood test for recent alcohol use
This study looks at a blood test that may tell how much alcohol a person has had recently, even after they've stopped drinking. It may help doctors better understand drinking patterns and health risks.
Denton, TexasAges 21 years+ - NCT05062707Recruiting
Study of early aging in young people during cancer treatment
This study looks at how “early aging” changes show up during treatment in young adults with cancer. It may help doctors better understand health effects during curative therapy and improve care for people your age.
GroningenAges 18–39 - NCT05124288Recruiting
Study immune changes after AML relapse after bone marrow transplant
This study looks at how the immune system changes when acute myeloid leukemia (AML) comes back after a donor stem cell transplant. It may help researchers create more personalized treatment plans and future guidelines for how to care for people in this situation.
Milan, MilanoAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,922 recruiting hematology studies from the U.S. registry right now, out of 7,323 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.